Wolfe Research initiated coverage of Abivax (ABVX) with an Outperform rating and $176 price target The company’s odds of success in Crohn’s disease may be higher than that of ulcerative colitis, the analyst tells investors in a research note. The firm says that with ulcerative colitis already succeeding, and with obefazimod having a better mechanism for Crohn’s disease, the Crohn’s readout is a better catalyst in 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax announces patient-reported outcomes from ABTECT trial
- Abivax initiated with an Overweight at Barclays
- Abivax price target raised, named a ‘Best Idea’ at Guggenheim
- Abivax price target raised to $120 from $112 at BTIG
- Abivax’s Obefazimod: Promising Clinical Results and Market Potential Drive Buy Rating